REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

This phase 2 study (N = 116) evaluated single-agent vosaroxin, a first-in-class anticancer quinolone derivative, in patients ≥60 years of age with previously untreated unfavourable prognosis acute myeloid leukaemia. Dose regimen optimization was explored in sequential cohorts (A: 72 mg/m(2) d 1, 8,...

Descripción completa

Detalles Bibliográficos
Autores principales: Stuart, Robert K, Cripe, Larry D, Maris, Michael B, Cooper, Maureen A, Stone, Richard M, Dakhil, Shaker R, Turturro, Francesco, Stock, Wendy, Mason, James, Shami, Paul J, Strickland, Stephen A, Costa, Luciano J, Borthakur, Gautam, Michelson, Glenn C, Fox, Judith A, Leavitt, Richard D, Ravandi, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354261/
https://www.ncbi.nlm.nih.gov/pubmed/25403830
http://dx.doi.org/10.1111/bjh.13214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354261/
https://www.ncbi.nlm.nih.gov/pubmed/25403830
http://dx.doi.org/10.1111/bjh.13214

Ejemplares similares